Antitumoral Activity of the Universal Methyl Donor S-Adenosylmethionine in Glioblastoma Cells
Molecules · 2024
DOI: 10.3390/molecules29081708 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Laura Mosca und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via Luigi De Crecchio 7, 80138 Naples, Italy. Hauptthemen laut MEDLINE: Glioblastoma, S-Adenosylmethionine, Apoptosis, Cell Proliferation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma (GBM), the most frequent and lethal brain cancer in adults, is characterized by short survival times and high mortality rates. Due to the resistance of GBM cells to conventional therapeutic treatments, scientific interest is focusing on the search for alternative and efficient adjuvant treatments. S-Adenosylmethionine (AdoMet), the well-studied physiological methyl donor, has emerged as a promising anticancer compound and a modulator of multiple cancer-related signaling pathways. We report here for the first time that AdoMet selectively inhibited the viability and proliferation of U87MG, U343MG, and U251MG GBM cells. In these cell lines, AdoMet induced S and G2/M cell cycle arrest and apoptosis and downregulated the expression and activation of proteins involved in homologous recombination DNA repair, including RAD51, BRCA1, and Chk1. Furthermore, AdoMet was able to maintain DNA in a damaged state, as indicated by the increased γH2AX/H2AX ratio. AdoMet promoted mitotic catastrophe through inhibiting Aurora B kinase expression, phosphorylation, and localization causing GBM cells to undergo mitotic catastrophe-induced death. Finally, AdoMet inhibited DNA repair and induced cell cycle arrest, apoptosis, and mitotic catastrophe in patient-derived GBM cells. In light of these results, AdoMet could be considered a potential adjuvant in GBM therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Via Luigi De Crecchio 7, 80138 Naples, Italy.
- Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Via Pansini 5, 80131 Naples, Italy.
- Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Via Luciano Armanni 5, 80138 Naples, Italy.
- Institute of Endocrinology and Experimental Oncology (IEOS), National Research Council (CNR), Via Pansini 5, 80131 Naples, Italy.
ORCID-Profile: Laura Mosca, Cristina Pagano, Marina Porcelli
Zitieren
APA
Mosca, L., Pagano, C., Tranchese, R. V., Grillo, R., Cadoni, F., Navarra, G., Coppola, L., Pagano, M., Mele, L., Cacciapuoti, G., Laezza, C., & Porcelli, M. (2024). Antitumoral Activity of the Universal Methyl Donor S-Adenosylmethionine in Glioblastoma Cells. Molecules. https://doi.org/10.3390/molecules29081708
Vancouver
Mosca L, Pagano C, Tranchese RV, Grillo R, Cadoni F, Navarra G, et al. Antitumoral Activity of the Universal Methyl Donor S-Adenosylmethionine in Glioblastoma Cells. Molecules. 2024. doi:10.3390/molecules29081708
BibTeX
@article{Mosca2024,
author = {Mosca, Laura and Pagano, Cristina and Tranchese, Roberta Veglia and Grillo, Roberta and Cadoni, Francesca and Navarra, Giovanna and Coppola, Laura and Pagano, Martina and Mele, Luigi and Cacciapuoti, Giovanna and Laezza, Chiara and Porcelli, Marina},
title = {Antitumoral Activity of the Universal Methyl Donor S-Adenosylmethionine in Glioblastoma Cells},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29081708}
}
EUVIMED